Anaveon presents new data on development compounds ANV700 and ANV600 at the Society for Immunotherapy of Cancer 2024 Annual Meeting

ANAVEON Biotech Cancer IL-2 Cytokines Bispecific Phase Clinical

Basel, Novmeber 9, 2024 – Anaveon, a clinical stage, immuno-oncology company, presents posters on ANV700 and ANV600 at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting being held from Friday, November 8, 2024, to Sunday, November 10, 2024, in Houston, Texas. Abstracts will be available online (Journal for ImmunoTherapy of Cancer (JITC)) from 8 a.m. CST on November 5, 2024.

Details of the poster presentations are:

Saturday, Nov. 9, 2024, 12:15 – 1:45 pm CST

Poster #960 (download poster #960 here)
Title: ANV700 is a novel proximity-activated IL-21 receptor agonist designed to selectively reinvigorate tumor-reactive PD-1 expressing T cells
Authors: A. Rau, N. Egli, P. Murer, L. Petersen, C. Stocker, K. Richter, C. Huber

Poster #954 (download poster #954 here)
Title: ANV600, a cis-signaling αPD-1/IL-2Rβ/γ agonist, expands both CD4+ and CD8+ tumor-specific T cells by acting in the tumor microenvironment and draining lymph nodes
Authors: P. Murer, A. Zurbach, L. Petersen, N. Egli, A. Katopodis, C. Huber

Latest News

21.05.2025

Anaveon announces presentation of a trial in progress poster to be presented at the American Society for Clinical Oncology 2025 Annual Meeting on Monday, June 2, 2025 in Chicago

– EXPAND-1 is a clinical study with ANV600, a novel PD-1 targeted IL-2R-βγ agonist, in monotherapy and in combination with pembrolizumab in cancer patients – Basel, May 21, 2025 – Anaveon, a clinical stage, immuno-oncology company, today announced that it will present a poster on…
Read more

19.05.2025

Basel Area Life-Science Ecosystem – Handelszeitung

Basel, May 15, 2025: See Anaveon’s contribution to the Handelszeitung special report on the status of Life Sciences in Basel: Handelszeitung
Read more

01.04.2025

Immuno-Oncology Progress: PragmaTIL Trial Receives Approval, with Anaveon as a Key Partner

As a key partner, we are proud to announce that PragmaTIL has received regulatory approval to launch its clinical trial, bringing safer and more effective cell therapy one step closer to cancer patients. 🔬 The trial will start at VHIO (Spain) and Herlev Hospital (Denmark),…
Read more

Corporate Positioning & Design, Concept, Webdesign & Code:
Schlatter corporate GmbH
Davidstrasse 45
CH-9000 St.Gallen
schlattercorporate.com